1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes.
Open Access
- 1 April 1996
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 97 (7), 1577-1588
- https://doi.org/10.1172/jci118582
Abstract
1,25(OH)2 Vitamin D3 (VD3) and retinoic acid (RA) function as ligands for nuclear receptors which regulate transcription. Though the cardiovascular system is not thought to represent a classical target for these ligands, it is clear that both cardiac myocytes and vascular smooth muscle cells respond to these agents with changes in growth characteristics and gene expression. In this study we demonstrate that each of these ligands suppresses many of the phenotypic correlates of endothelin-induced hypertrophy in a cultured neonatal rat cardiac ventriculocyte model. Each of these agents reduced endothelin-stimulated ANP secretion in a dose-dependent fashion and the two in combination proved to be more effective than either agent used alone (VD3: 49%; RA:52%; VD3 + RA:80% inhibition). RA, at concentrations known to activate the retinoid X receptor, and, to a lesser extent, VD3 effected a reduction in atrial natriuretic peptide, brain natriuretic peptide, and alpha-skeletal actin mRNA levels. Similar inhibition (VD3:30%; RA:33%; VD3 + RA:59% inhibition) was demonstrated when cells transfected with reporter constructs harboring the relevant promoter sequences were treated with VD3 and/or RA for 48 h. These effects were not accompanied by alterations in endothelin-induced c-fos, c-jun, or c-myc gene expression, suggesting either that the inhibitory locus responsible for the reduction in the mRNA levels lies distal to the activation of the immediate early gene response or that the two are not mechanistically coupled. Both VD3 and RA also reduced [3H]leucine incorporation (VD3:30%; RA:33%; VD3 + RA:45% inhibition) in endothelin-stimulated ventriculocytes and, once again, the combination of the two was more effective than either agent used in isolation. Finally, 1,25(OH)2 vitamin D3 abrogated the increase in cell size seen after endothelin treatment. These findings suggest that the liganded vitamin D and retinoid receptors are capable of modulating the hypertrophic process in vitro and that agents acting through these or similar signaling pathways may be of value in probing the molecular mechanisms underlying hypertrophy.This publication has 49 references indexed in Scilit:
- Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure.Journal of Clinical Investigation, 1995
- Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptorsCell, 1991
- 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells.Journal of Clinical Investigation, 1991
- The cardiac beta-myosin heavy chain isogene is induced selectively in alpha 1-adrenergic receptor-stimulated hypertrophy of cultured rat heart myocytes.Journal of Clinical Investigation, 1990
- Human and canine gene homologs of porcine brain natriuretic peptideBiochemical and Biophysical Research Communications, 1989
- Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries.Journal of Clinical Investigation, 1989
- Identification of a receptor for the morphogen retinoic acidNature, 1987
- Effects of cytochalasin and phalloidin on actin.The Journal of cell biology, 1987
- Vitamin D3 and cardiovascular function in rats.Journal of Clinical Investigation, 1987
- Isolation of biologically active ribonucleic acid from sources enriched in ribonucleaseBiochemistry, 1979